BNP Paribas Arbitrage SA Grows Holdings in Repligen Co. (RGEN)

BNP Paribas Arbitrage SA raised its position in shares of Repligen Co. (NASDAQ:RGEN) by 314.6% during the first quarter, HoldingsChannel reports. The firm owned 8,984 shares of the biotechnology company’s stock after purchasing an additional 6,817 shares during the period. BNP Paribas Arbitrage SA’s holdings in Repligen were worth $531,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Huntington National Bank purchased a new stake in Repligen during the first quarter valued at about $25,000. First Hawaiian Bank purchased a new stake in Repligen during the fourth quarter valued at about $28,000. Mascoma Wealth Management LLC purchased a new stake in Repligen during the first quarter valued at about $41,000. Enlightenment Research LLC purchased a new stake in Repligen during the fourth quarter valued at about $42,000. Finally, Parallel Advisors LLC raised its position in Repligen by 485.1% during the fourth quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 1,043 shares in the last quarter. Institutional investors and hedge funds own 90.89% of the company’s stock.

In other news, CEO Anthony Hunt sold 7,475 shares of the firm’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $59.01, for a total transaction of $441,099.75. Following the transaction, the chief executive officer now directly owns 250,132 shares of the company’s stock, valued at $14,760,289.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Ralf Kuriyel sold 2,240 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $58.53, for a total value of $131,107.20. Following the transaction, the vice president now directly owns 21,043 shares in the company, valued at $1,231,646.79. The disclosure for this sale can be found here. Insiders have sold 48,437 shares of company stock worth $2,855,032 over the last ninety days. Insiders own 1.70% of the company’s stock.

RGEN has been the topic of a number of research reports. Zacks Investment Research upgraded Repligen from a “hold” rating to a “strong-buy” rating and set a $80.00 price target on the stock in a research report on Tuesday. ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 4th. Finally, BidaskClub downgraded Repligen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $64.20.

Shares of NASDAQ:RGEN opened at $67.71 on Thursday. Repligen Co. has a 12-month low of $41.36 and a 12-month high of $71.21. The stock has a market cap of $3.18 billion, a PE ratio of 92.75, a P/E/G ratio of 4.26 and a beta of 1.13. The company has a current ratio of 2.18, a quick ratio of 1.84 and a debt-to-equity ratio of 0.03.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.02. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The firm had revenue of $60.63 million for the quarter, compared to analysts’ expectations of $55.09 million. During the same period last year, the firm earned $0.17 earnings per share. The company’s revenue for the quarter was up 35.3% compared to the same quarter last year. As a group, analysts anticipate that Repligen Co. will post 0.9 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This news story was originally published by WKRB News and is the property of of WKRB News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.wkrb13.com/2019/05/16/bnp-paribas-arbitrage-sa-grows-holdings-in-repligen-co-rgen.html.

Repligen Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Further Reading: What is the Bid-Ask Spread?

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.